Compare FPI & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FPI | OVID |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.9M | 421.8M |
| IPO Year | 2013 | 2017 |
| Metric | FPI | OVID |
|---|---|---|
| Price | $8.58 | $2.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $6.40 |
| AVG Volume (30 Days) | 742.1K | ★ 1.8M |
| Earning Date | 10-28-2026 | 11-16-2026 |
| Dividend Yield | ★ 4.27% | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $52,178,000.00 | $7,252,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $8.35 | $1.18 |
| 52 Week High | $13.23 | $3.11 |
| Indicator | FPI | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 24.48 | 50.51 |
| Support Level | N/A | $2.09 |
| Resistance Level | $9.96 | $2.44 |
| Average True Range (ATR) | 0.33 | 0.20 |
| MACD | -0.20 | 0.04 |
| Stochastic Oscillator | 10.02 | 53.28 |
Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.